Table 1.
Baseline characteristics.
| Cohort | PS Matched cohort | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Entecavir | Tenofovir | p-value | Entecavir | Tenofovir | p-value | |||||
| N | 5348 | 1900 | 3304 | 1652 | ||||||
| Age, year (SD) | 54 | 11.92 | 51 | 12.19 | < 0.001 | 52 | 11 | 52 | 12 | 0.989 |
| Gender | 0.072 | 0.966 | ||||||||
| Male | 3544 | 66% | 1302 | 69% | 2210 | 67% | 1106 | 67% | ||
| Female | 1804 | 34% | 598 | 31% | 1094 | 33% | 546 | 33% | ||
| BMI, mean (SD) | 24.65 | 4.33 | 24.85 | 4.38 | 0.143 | 24.7 | 4.1 | 24.8 | 4.4 | 0.644 |
| Comorbidity, N (%) | ||||||||||
| Liver cirrhosis | 1590 | 30% | 590 | 31% | 0.347 | 930 | 28% | 509 | 31% | 0.732 |
| DM | 1165 | 22% | 336 | 18% | < 0.001 | 632 | 19% | 310 | 19% | 0.759 |
| Prior NA use* | 460 | 9% | 440 | 23% | < 0.001 | 268 | 8% | 383 | 23% | < 0.001 |
| cDDDs, mean (SD) | 647.4 | 576.8 | 907.4 | 695.6 | < 0.001 | 658.4 | 573.3 | 913.7 | 699.9 | < 0.001 |
| Stratified cDDD, N (%) | < 0.001 | < 0.001 | ||||||||
| cDDDs ≤ 1095 | 4377 | 82% | 1266 | 67% | 2682 | 81% | 1094 | 66% | ||
| cDDDs > 1095 | 971 | 18% | 634 | 33% | 622 | 19% | 558 | 34% | ||
| Follow-up (years) | 0.050 | 0.025 | ||||||||
| Mean (SD) | 3.30 | 2.05 | 3.34 | 1.84 | 3.34 | 2.03 | 3.42 | 1.85 | ||
| Median (Q1–Q3) | 2.95 | 1.47–4.83 | 3.16 | 1.72–4.94 | 3.01 | 1.53–4.88 | 3.26 | 1.78–5.01 | ||
| Lab data, mean (SD) | ||||||||||
| Creatinine (mg/dL) | 1.05 | 1.33 | 0.90 | 0.89 | 0.755 | 0.98 | 1.18 | 0.9 | 1.0 | 0.468 |
| AST (U/L) | 165 | 397 | 165 | 349 | 0.002 | 166 | 405 | 166 | 355 | 0.062 |
| ALT (U/L) | 213 | 469 | 233 | 459 | < 0.001 | 227 | 496 | 228 | 458 | 0.002 |
| Platelet (103/μL) | 181 | 87 | 18 | 72 | 0.206 | 182 | 82 | 179 | 74 | 0.940 |
| AFP (ng/mL) | 169 | 6669 | 26 | 115 | 0.003 | 30 | 444 | 27 | 122 | 0.003 |
| Albumin (g/dL) | 3.96 | 0.69 | 4.15 | 0.61 | < 0.001 | 4.08 | 0.62 | 4.1 | 0.6 | 0.734 |
| Bilirubin (mg/dL) | 2.07 | 4.14 | 1.87 | 3.56 | 0.002 | 1.95 | 3.94 | 1.9 | 3.7 | 0.001 |
| INR | 1.16 | 0.28 | 1.14 | 0.27 | 0.006 | 1.15 | 0.26 | 1.1 | 0.3 | 0.928 |
| HBV DNA (log IU/mL) | 3.5 | 2.32 | 3.18 | 2.29 | 0.150 | 3.38 | 2.29 | 3.1 | 2.3 | 0.171 |
| HBeAg positive, N (%) | 849 | 16% | 544 | 29% | < 0.001 | 586 | 18% | 435 | 26% | < 0.001 |
| FIB-4 | < 0.001 | 0.807 | ||||||||
| Mean (SD) | 4.28 | 6.54 | 3.53 | 4.66 | 3.73 | 4.79 | 3.76 | 4.91 | ||
| Median (Q1-Q3) | 2.32 | 1.35–4.71 | 2.11 | 1.25–3.80 | 2.24 | 1.32–4.31 | 2.24 | 1.33–4.14 | ||
| APRI | 0.126 | 0.200 | ||||||||
| Mean (SD) | 3.75 | 11.00 | 3.41 | 8.19 | 3.53 | 9.87 | 3.52 | 8.52 | ||
| Median (Q1–Q3) | 1.08 | 0.48–2.77 | 1.10 | 0.55–2.57 | 1.09 | 0.50–2.61 | 1.11 | 0.54–2.63 | ||
| CTP class | < 0.001 | 0.469 | ||||||||
| A | 4214 | 79% | 1584 | 83% | 2741 | 83% | 1355 | 82% | ||
| B | 877 | 16% | 268 | 14% | 458 | 14% | 249 | 15% | ||
| C | 257 | 5% | 48 | 3% | 105 | 3% | 48 | 3% | ||
| CCI, N (%) | < 0.001 | 0.003 | ||||||||
| 0 | 134 | 3% | 52 | 3% | 90 | 3% | 30 | 2% | ||
| 1–2 | 2188 | 41% | 1087 | 57% | 1606 | 49% | 881 | 53% | ||
| ≥ 3 | 3026 | 57% | 761 | 40% | 1608 | 49% | 741 | 45% | ||
| Mean (SD) | 3.32 | 2.19 | 2.66 | 1.90 | < 0.001 | 2.86 | 1.90 | 2.85 | 1.94 | 0.520 |
| Median (Q1–Q3) | 3 | 2–5 | 2 | 1–4 | 2 | 1–4 | 2 | 1–4 | ||
PS propensity score, SD standard deviation, BMI body mass index, DM diabetes mellitus, NA nucleos(t)ide analogue, cDDD cumulative defined daily doses (DDDs), AST aspartate aminotransferase, ALT alanine aminotransferase, AFP alpha-fetoprotein, INR international normalized ratio, HBV hepatitis B virus, HBeAg hepatitis B e antigen, FIB-4 fibrosis index based on 4 factors, APRI AST to platelet ratio index, CTP Child–Turcotte–Pugh, CCI Charlson comorbidity index.
*Lamivudine, telbivudine, adefovir.